Lonza Group

Loyal to its 1897 roots in the Swiss Alps, Lonza has evolved into an indispensable global Contract Development and Manufacturing Organization (CDMO). It is a premier partner for the pharmaceutical, biotech, and nutrition markets, offering extensive, integrated manufacturing services for small molecules, complex biologics, cell and gene therapies, and mRNA technologies.

The company provides an end-to-end supply chain solution spanning early preclinical development, rigorous clinical trials, and massive commercial-scale production. Its flagship site in Visp, Switzerland, stands out as one of the world’s most technologically sophisticated biomanufacturing hubs. This site houses Lonza’s highly innovative Ibex® Solutions, which deliver flexible, bespoke manufacturing models that dramatically accelerate time-to-market while minimizing financial risk.

Lonza gained immense global recognition for its agility and scale when it rapidly executed the commercial manufacturing of the active ingredient for Moderna’s COVID-19 mRNA vaccine. Characterized by its relentless focus on technological innovation, stringent quality control, and robust global infrastructure, Lonza continues to be a foundational pillar in modern medical manufacturing, directly enabling the commercialization of life-saving therapeutics.